Dr. Moore brings extensive drug development and clinical expertise to the company’s development team. He has 26 years of senior management experience in pharmaceutical research and development including 23 years with increasingly senior responsibilities at Procter & Gamble. During his extensive working history, Dr. Moore has completed 11 investigational new drug (IND) applications or supplemental INDs, 15 phase I studies, 12 phase II studies, 7 phase III studies (plus 2 additional phase III studies that are still in progress) and 2 new drug applications. One of Dr. Moore’s completed phase III studies enrolled 4,000 patients and included centres in 26 countries.

Dr. Moore obtained a Ph.D. in pharmacology in 1974 from the University of Aston in Birmingham, England. From 1977 to 1979 he was Assistant Professor of Pharmacology at the Institute for Cardiovascular Studies and Department of Pharmacology at the University of Houston. From 1979 to 1982 he was Unit Leader, Pharmacology and Senior Research Scientist at Norwich Eaton Pharmaceuticals. Following the acquisition of Norwich Eaton by Procter & Gamble, Dr. Moore held increasingly senior positions as Section Chief, Director of Research, and then Director of New Drug Development before assuming his most recent role from 1998 to 2002 as General Manager, Cardiac R&D. Prior to joining Stem Cell Therapeutics, Dr Moore was Executive VP, clinical development and regulatory affairs at Cardiome Pharma Corp. from 2002 through end of 2004, where he was responsible for all clinical and regulatory activities.

Mr. Barry Herring has 25 years experience as an accounting executive for companies in Canada and the United States. He has been a senior executive in public and private corporations within the energy and mining sector. Prior to joining SCT, Mr. Herring was the President, CFO and Director of Atlas Minerals Inc. Prior thereto he was the CFO of Velo Energy Ltd., a start-up Oil and Gas Exploration Company. He has served as Vice President of Finance and CFO for the following companies, TerraWest Energy Corp., Hawker Resources Inc., and Southward Energy Ltd.

Mr. Herring became a Chartered Accountant in 1983 from the Institute of Chartered Accountants of Alberta. He started his career in accounting in 1981 at Price Waterhouse. In 1987, Mr. Herring joined Oakwood Petroleum and worked as a corporate accountant until joining Calpine Natural Gas Ltd., in 1989 where he held increasingly senior positions until his departure in 2001.

In addition to his corporate experience, Mr. Herring has taught accounting and tax at the post secondary level and chaired several committees on Information Systems development and implementation.

Dr. Davidoff brings a multi-faceted skill set ranging from business, drug development, regulatory and clinical development expertise to his position as VP, Product Development of Stem Cell Therapeutics Corp. Simultaneous with the completion of a Ph.D. in Integrative Cardiovascular Physiology in 2002 from the University of Calgary, he acted as a Biotechnology Analyst with Lightyear Capital Inc. He has 7 years of senior management experience in bio-pharmaceutical research and development of increasingly senior responsibilities; first with Cardiome Pharma Corp. as Senior Clinical Scientist and Head of Pharmacology, and then as Co-founder, Director, and VP, Product Development of Neurogenesis Biotech Corp. which was renamed to Stem Cell Therapeutics Corp. prior to the Company’s initial public offering in January of 2005. During his extensive work history, Dr. Davidoff has completed 7 investigational new drug (“IND”) applications or supplemental IND’s, 1 phase I study, and 5 phase II studies, in the US, Canada and India. Dr. Davidoff has also over 45 peer reviewed publications, presentations, abstracts and seminars spanning areas of heart and kidney transplant immunology, cardiac physiology, congestive heart failure and stem cell neural physiology. Dr. Davidoff currently acts as the VP, Product Development and is responsible for drug development, clinical research & regulatory affairs with Stem Cell Therapeutics Corp.